Table 3.
BCVA outcomes according to LHON genotypes.
| All patients (N = 88 eyes) | ND4 patients (N = 54 eyes) | ND1 patients (N = 16 eyes) | ND6 patients (N = 18 eyes) | ND4 patients aged ≥ 15 at onset (N = 46 eyes) | ND4 patients aged ≥ 15 at onset and treated with idebenone (N = 30 eyes) | |
|---|---|---|---|---|---|---|
| Time from onset to last visit (months) | ||||||
| Mean (SD) | 32.2 (24.0) | 36.3 (29.5) | 26.0 (5.8) | 25.6 (8.6) | 36.8 (31.8) | 40.5 (38.0) |
| Presymptomatic BCVA (LogMAR)a | 0 | 0 | 0 | 0 | 0 | 0 |
| Last-observed BCVA (LogMAR) | ||||||
| Mean (SD) | 1.37 (0.78) | 1.46 (0.63) | 1.52 (1.06) | 0.97 (0.83) | 1.55 (0.62) | 1.57 (0.62) |
| 95% CI | 1.15, 1.59 | 1.17, 1.74 | 1.00, 2.04 | 0.48, 1.46 | 0.96, 1.54 | 0.71, 1.52 |
| Median | 1.30 | 1.47 | 1.60 | 0.75 | 1.60 | 1.60 |
| Minimum, maximum | 0.00, 4.00 | 0.00, 2.30 | 0.10, 4.00 | 0.00, 2.30 | 0.00, 2.30 | 0.10, 2.30 |
| Q1, Q3 | 0.80, 2.00 | 1.10, 2.00 | 0.00, 2.00 | 0.22, 2.00 | 1.20, 2.00 | 1.10, 2.00 |
BCVA best-corrected visual acuity; SD standard deviation.
aMissing presymptomatic BCVA were assigned a value of 0 LogMAR (normal visual acuity).